Bio Behavioral Health (BBH) has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials.
The collaboration enhances PhaseWell’s network and strengthens its presence in neurologic and psychiatric research, aligning with the rising demand for research in these areas of medicine.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PhaseWell seeks to boost participation in trials by working with high-performing sites and community practices across the US. The integration of BBH further strengthens its expertise in central nervous system (CNS) research.
BBH brings experience in conducting clinical trials focused on data quality, patient-centred care, and efficient study execution within community settings.
This partnership aims to broaden research opportunities for patients while offering sponsors consistent enrolment and operational performance.
PhaseWell provides comprehensive Phase I–IV trial services spanning CNS, oncology, dermatology, and cardiovascular/metabolic.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPhaseWell CEO Carsten Bick said. “Partnering with Bio Behavioral Health aligns perfectly with our mission to expand access to complex clinical research in the community setting.
“Neuropsychiatric disorders represent a critical and growing area of unmet need in the US, but the medical science coming down the pike is potentially game-changing for this patient population. By combining PhaseWell’s national platform with BBH’s expertise and community reach within the therapeutic area, we are improving our position to increase patient access to this incredibly important next generation of therapeutics.”
BBH founder and leading principal investigator Dr Ashok Patel said: “Joining PhaseWell Research allows us to scale our impact while staying true to our mission of delivering compassionate, community-based neuropsychiatric research.
“Together, we can broaden access to clinical trials for patients, strengthen partnerships with sponsors and CROs, and continue advancing high-quality research that meaningfully contributes to the advancement of medicine in our space.”
